Trevi Therapeutics (TRVI) Research & Development (2018 - 2025)

Trevi Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $6.2 million for Q4 2025.

• In Q4 2025, Research & Development fell 33.61% year-over-year to $6.2 million; the TTM figure through Dec 2025 stood at $35.0 million (down 11.13% YoY), while the FY2025 annual figure was $33.5 million, down 14.98% from the prior year.
• Research & Development was $6.2 million for Q4 2025 at Trevi Therapeutics, down from $10.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $11.2 million in Q3 2024 to a low of $4.3 million in Q4 2022.
• Historically, Research & Development has averaged $6.9 million across 5 years, with a median of $6.2 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Research & Development soared 77.51% in 2024, then sank 33.61% in 2025.
• A 5-year view of Research & Development shows it stood at $6.2 million in 2021, then plunged by 30.13% to $4.3 million in 2022, then soared by 50.98% to $6.5 million in 2023, then soared by 43.11% to $9.3 million in 2024, then slumped by 33.61% to $6.2 million in 2025.
• The last three Research & Development figures came in at $6.2 million (Q4 2025), $10.1 million (Q3 2025), and $9.4 million (Q2 2025), per Business Quant data.